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Background: The role of interferon-g release assay (IGRA) in monitoring responses to anti-tuberculosis (TB)
treatment is not clear. We evaluated the results of the QuantiFERON-TB Gold In-tube (QFT-GIT) assay over time
during the anti-TB treatment of adults with no underlying disease.
Methods: We enrolled soldiers who were newly diagnosed with active TB and admitted to the central referral
military hospital in South Korea between May 1, 2008 and September 30, 2009. For each participant, we preformed
QFT-GIT assay before treatment (baseline) and at 1, 3, and 6 months after initiating anti-TB medication.
Results: Of 67 eligible patients, 59 (88.1%) completed the study protocol. All participants were males who were
human immunodeficiency virus (HIV)-negative and had no chronic diseases. Their median age was 21 years (range,
20-48). Initially, 57 (96.6%) patients had positive QFT-GIT results, and 53 (89.8%), 42 (71.2%), and 39 (66.1%) had
positive QFT-GIT results at 1, 3, and 6 months, respectively. The IFN-g level at baseline was 5.31 ± 5.34 IU/ml, and
the levels at 1, 3, and 6 months were 3.95 ± 4.30, 1.82 ± 2.14, and 1.50 ± 2.12 IU/ml, respectively. All patients had
clinical and radiologic improvements after treatment and were cured. A lower IFN-g level, C-reactive protein ≥ 3
mg/dl, and the presence of fever (≥ 38.3°C) at diagnosis were associated with negative reversion of the QFT-GIT
assay.
Conclusion: Although the IFN-g level measured by QFT-GIT assay decreased after successful anti-TB treatment in
most participants, less than half of them exhibited QFT-GIT reversion. Thus, the reversion to negativity of the QFT-
GIT assay may not be a good surrogate for treatment response in otherwise healthy young patients with TB.
Background
Tuberculosis (TB) remains one of the most significant
infectious diseases worldwide. Despite intensive global
efforts, the number of new TB cases continues to
increase, with 9.27 million new cases and 1.78 million
deaths in 2006 [1]. Rapid diagnosis and appropriate
treatment of TB are important not only for the health
of individuals but also for effective disease control in a
population. To evaluate treatment efficacy, sputum
microscopy is still used, despite its reportedly low sensi-
tivity [2].
T h ei n t e r f e r o n - g a m m ar e l e a s ea s s a y( I G R A )h a s
recently been adopted for detecting TB infection [3]. Its
role in the diagnosis of latent TB infection (LTBI) is
promising [4], and it has some advantages over the
tuberculin skin test (TST): it is not affected by previous
Bacille Calmette-Guérin (BCG) vaccination, it minimizes
technical errors, and it has higher specificity [5]. How-
ever, its application in assessing treatment efficacy is not
clear [6]. Several reports have suggested that the IGRA
is useful for evaluating the efficacy of treatment for
active TB, although most of the studies enrolled a small
number of patients or those with various immune sta-
tuses [7-10].
To examine the potential of the IGRA as a surrogate
for treatment response among young immunocompetent
patients with TB, we evaluated the sequential changes in
the interferon-gamma (IFN-g) level measured by the
QuantiFERON-TB Gold In-tube (QFT-GIT; Cellestis,
Victoria, Australia) assay in immunocompetent adults
with TB, but with no underlying disease.
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Participants and data collection
All soldiers who were diagnosed with active TB between
May 2008 and September 2009 at the Armed Forces
Capital Hospital, a central referral military hospital in
South Korea, were eligible for this study. Those who
could not be followed for at least 6 months or who
received anti-TB medication before admission to our
hospital were excluded. After giving informed consent,
each participant completed a questionnaire regarding
their demographics, history of TB, smoking status, and
other factors. We performed QFT-GIT assay for each
participant before treatment (baseline) and after 1, 3,
and 6 months of anti-TB treatment. This study was
reviewed and approved by the Institutional Review
Board of the Armed Forces Medical Command.
Diagnosis and treatment of TB
Active pulmonary TB was diagnosed when (1) the
patient’s sputum was positive for acid-fast staining, or
Mycobacterium tuberculosis was cultured; or (2) the
patient’s data met the definition of a clinical case of TB
according to the World Health Organization criteria [11].
To diagnose clinical TB, respiratory symptoms and radio-
graphic lesions on high-resolution computed tomography
(HRCT) that were compatible with active TB were man-
datory. Active pulmonary TB was defined as the presence
of cavities, branching linear opacities, or multiple non-
calcified nodules on HRCT [12-14]. For participants with
lesions that suggested active TB, but who did not have
positive acid-fast smears or M. tuberculosis cultures,
broad-spectrum antibiotics (a combination of a third-
generation cephalosporin and a macrolide) were pre-
scribed for 1 week; if the lesions on chest X-ray or HRCT
showed a definite improvement, a diagnosis of active TB
was excluded.
TB pleuritis was diagnosed when (1) M. tuberculosis
was detected in a culture of pleural fluid or tissue; or
(2) positive real-time polymerase chain reaction for
M. tuberculosis in pleural fluid or tissue; or (3) an exu-
dative pleural effusion showed lymphocyte predomi-
nance, negative cytology, low carcinoembryonic antigen
(< 5 ng/ml), and high adenosine deaminase (≥ 50 IU/L).
TB lymphadenitis was diagnosed when one of the fol-
lowing criteria was met: (1) cultivation of M. tuberculosis
from lymph node tissue; (2) presence of a caseating granu-
loma with or without visible acid-fast bacilli; or (3) positive
real-time polymerase chain reaction for M. tuberculosis in
lymph node tissue.
All patients were given standardized anti-TB medica-
tion consisting of daily isoniazid (INH), rifampicin
(RMP), ethambutol (EMB), and pyrazinamide (PZA) for
2 months, followed by daily INH, RMP, and EMB for
4 months [15]. In cases with INH resistance, daily RMP,
EMB, PZA, and a fluoroquinolone (levofloxacin or mox-
ifloxacin) were given for at least 6 months.
Tuberculin skin test
After the initial blood sampling for the QFT-GIT assay,
a TST was performed by trained personnel following
standard procedures. For this test, 0.1 ml (2 TU) of pur-
ified protein derivate (RT23, Statens Serum Institute,
Copenhagen, Denmark) was injected intradermally into
the inner side of the left forearm. The transverse
induration at the TST site was measured in millimeters
after 48-72 h, by one of three experienced nurses. We
defined a positive test as one in which there was
induration ≥ 10 mm [16].
Interferon-gamma release assay
The QFT-GIT was performed according to the manufac-
turer’s instructions. Blood was collected in three special
tubes: one coated with the Mycobacterium-tuberculosis-
specific peptides ESAT-6, CFP-10, and TB 7.7 (Rv2654,
only peptide 4); one coated with mitogen, as a positive
control; and one without antigen coating, as a negative
control. Within 8 h of blood sampling, the tubes were
incubated for 24 h at 37°C, centrifuged, and stored in the
cold until testing, as specified by the manufacturer. The
plasma IFN-g concentration was measured using a com-
mercial QFT-GIT ELISA and was determined as nega-
tive, intermediate, or positive (cut-off at 0.35 IU/ml) by
the manufacturer’s software. QFT-GIT reversion to nega-
tivity was defined as a change in the IFN-g level from a
positive (≥ 0.35 IU/ml) to a negative result (< 0.35 IU/
ml). Because the QFT-GIT ELISA cannot measure IFN-g
values > 10 IU/ml [7] accurately, values > 10 IU/ml were
treated as 10 IU/ml.
Statistical analysis
Agreement between the TST and QFT-GIT results was
measured using the kappa statistic. McNemar’st e s tw a s
used to compare paired proportions of QFT-GIT-posi-
tive results. Repeated measures analysis of variance was
used to compare the IFN-g levels at different time
points, and the results were validated using Mauchly’s
test of sphericity (equal variance of the differences
between levels of the repeated measures factor). The
means of different groups were compared using Stu-
dent’s t-test. The relationship between clinical character-
istics and QFT-GIT reversion to negativity was
evaluated using the c
2 test. Statistical significance was
assessed at a two-tailed P value of 0.05, and all data are
presented as the mean ± standard deviation except
figure 3. All statistical analyses were conducted using
PASW 17.0 (SPSS, Chicago, IL, USA).
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Demographic and clinical characteristics of the
participants
Sixty-seven soldiers with active TB were eligible for this
study; eight were lost to follow-up. Thus, 59 (87.9%)
participants completed the study protocol and were
included in the final analysis. All participants were male
and had a median age of 21 years (range, 20-48). Every
participant was negative for human immunodeficiency
virus (HIV) and had no other underlying disease (e.g.
uncontrolled asthma, diabetes mellitus, and chronic
renal failure). Forty-six (78.0%) patients had pulmonary
TB: 13 (28.9%) had positive acid-fast staining of their
sputum, and 33 (71.7%) had M. tuberculosis cultured
from their sputum. In 29 of these 33 participants, the
isolates were sensitive to all anti-TB medications; the
isolates from four patients showed INH mono-resis-
tance. Patients with other types of TB included 11 with
pleural TB (including one patient with culture-positive
pleural fluid), one with TB lymphadenitis, and one with
a TB abscess in the inguinal area (Table 1). All 11
patients with pleural TB and the one patient with a TB
abscess had pulmonary parenchymal involvement[17].
All patients in the study had radiologic and clinical
improvements, with negative conversion in a sputum
exam at 2 months after anti-TB treatment. None of the
59 patients had a relapse of active TB during the follow-
up period of 102 ± 105 days (range, 0-433).
Changes in QFT-GIT during anti-TB treatment
Fifty-seven (96.6%) patients had positive QFT-GIT
results and 56 (94.9%) had positive TST results at the
diagnosis of TB. The agreement between the two tests
was substantial (kappa = 0.79, P < 0.001) [18], with an
agreement rate of 98.3%. After treatment, 53 (89.8%)
had a positive QFT-GIT result at 1 month; 42 (71.2%),
at 3 months; and 39 (66.1%), at 6 months. The propor-
tion of patients with a positive QFT-GIT result
decreased significantly at 3 months (P < 0.001; Figure 1).
The IFN-g level at baseline was 4.38 ± 3.59 IU/ml, and
the levels at 1, 3, and 6 months were 3.51 ± 3.23 IU/ml,
1.80 ± 2.07 IU/ml, and 1.41 ± 1.88 IU/ml, respectively.
The IFN-g level decreased with time, with a significant
decrease at 3 months (P < 0.001), but not at 1 month
(P =0 . 1 6 ) .T h eI F N - g level did not differ significantly
between 3 and 6 months (P = 0.25, Figure 2). The IFN-g
level decreased during treatment in 55 (93.2%) partici-
pants. The mean difference in the IFN-g level between
baseline and 6 months was -3.75 ± 4.60 IU/ml, and the
ratio of the IFN-g level at 6 months to that at baseline
was 0.41 ± 0.58. The IFN-g level at 6 months was less
than half of the baseline level in 43 (72.9%) participants
(Table 2). Throughout the treatment, the IFN-g levels
had been lower among TB patients with pleural effusion
than among patients without pleural effusion. (Figure 3)
Participants with unusual change of IFN-g response
Three participants showed increased IFN-g levels after
treatment, with levels increasing from 1.89 to 2.02, 0.42 to
1.49, and 0.98 to 2.19 IU/ml, respectively. In one partici-
pant, the IFN-g level remained at 1.87 IU/ml. Two patients
with an initial negative QFT-GIT result remained persis-
tently QFT-GIT negative for 6 months (Figure 2).
One subjects with TB lymphadenitis had an IFN-g
level of > 10.0 IU/ml persistently during 6 months of
treatment and he was the only participant whose IFN-g
level exceeded 10 IU/ml after completing therapy. His
neck lymph node had a longest diameter of 4 cm at
baseline, but was undetectable at treatment completion,
and there was no evidence of relapse for 6 months after
treatment completion.
Characteristics associated with negative conversion of the
QFT-GIT
C-reactive protein (CRP) level higher than 3 mg/ml (P =
0.046) and body temperature above 38.3°C (P =0 . 0 5 6 )
at diagnosis were associated with reversion to negativity
of the QFT-GIT, as was a lower baseline IFN-g level
(P = 0.03, Table 3).
Discussion
This study reports the changes over time in the IFN-g
levels of young active TB patients with no underlying
disease, during treatment with anti-TB medication. All
59 patients were cured; however, only 18 (32.1%) of the
56 participants with an initial positive QFT-GIT result
showed reversion to negativity after 6 months of anti-
TB medication. With 6 months of treatment, the IFN-g
level decreased to less than half of the baseline level in
43 (72.9%) participants.
Table 1 Demographic and clinical characteristics of the
participants included in the final analysis
Characteristics Values (n = 59)
Median age: years (range) 21 (20-48)
Male: n (%) 59 (100)
BCG scar present: n (%) 44 (74.6)
Current smoker 26 (44.1)
Diagnosis
Pulmonary TB (%) 46 (78.0)
Smear positive 13 (28.9)*
Culture positive 33 (71.7)*
TB pleuritis 11 (18.6)
TB lymphadenitis 1 (1.7)
TB abscess 1 (1.7)
* The percentages were calculated using participants with pulmonary TB as
the denominator.
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for monitoring the efficacy of anti-TB therapy in patients
with active TB [19]. However, subsequent studies reported
discrepant results [3]. Longitudinal studies using a Quanti-
FERON-TB Gold (QFT-G) assay gave variable results.
Two studies conducted in Japan showed a progressive
decrease of the IFN-g response after anti-TB treatment,
with smaller percentages of subjects with positive QFT-G
results over time [20,21]. By contrast, a study conducted
in India showed a persistent IFN-g response during
treatment, with positive QFT-G rates of 73% at baseline
and 79% at 6 months, although the average IFN-g level
declined slightly [7]. This discrepancy may be related to
the initial IFN-g levels and the burden of TB in the coun-
tries. The baseline IFN-g level in the study conducted in
India was 4.09 ± 4.14 IU/ml, which was greater than those
in the two studies from Japan (0.51 ± 0.15 and 0.75 ± 0.15
IU/ml), and a higher IFN-g level was reported to be asso-
ciated with a lower likelihood of converting to a negative
culture [10]. Furthermore, in high-burden countries,
Figure 1 The proportion of active tuberculosis patients with positive QFT-GIT results.
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T-cell responses strong, even after the antigen load has
declined with therapy.
The lower reversion rate after completing anti-TB
treatment (31.6%) in our study could be explained by
the fact that the initial IFN-g level (4.38 ± 3.59 IU/ml)
was higher than those in the previous studies in Japan.
The higher initial IFN-g level in our study may be
associated with the demographic characteristics of the
participants, who were young, immunocompetent
patients with no underlying disease. To achieve rever-
sion to negativity in patients with a high initial IFN-g
level, the absolute decrease must be profound.
In addition to low baseline IFN-g level, higher CRP
level and the presence of fever were also associated with
the reversion to negativity of QFT-GIT in this study.
Figure 2 The change in the IFN-g level during successful anti-TB treatment.
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association between fever and reversion to negativity
may be due to the small number of participants. IL-12-
dependent IFN-g release is crucial for controlling TB
infection [22,23]. Therefore, relatively weak immune
responses with lower IFN-g release may be related to a
severe initial infectious state, presenting as fever and a
high CRP level. Reversion to negativity of the QFT-GIT
in these patients may be achieved easily because of the
lower initial IFN-g level.
Interestingly, TB patients with pleural effusion had
consistently lower IFN- g levels than those without
pleural effusion throughout the treatment period. Con-
sidering the fact that the development of tuberculous
pleural effusion is suggested to be based on delayed type
hypersensitivity reaction [24,25], lower IFN- g levels
among TB patients with effusion was somewhat unex-
pected. This observation should be confirmed in future
studies involving larger number of patients.
In this study, 96.6% of the participants with active TB
had positive results on the first QFT-GIT; this rate is
higher than previously reported rates. With the exception
of two studies from South Korea [26] and Japan [20], most
studies reported low sensitivity (64-76%) with this assay
[27-31]. The higher sensitivity of the assay in our study
could be explained by the characteristics of the partici-
pants, who were mostly young, otherwise healthy, immu-
nocompetent military personnel. The sensitivity of the
IGRA is known to decrease significantly with older age
[32], HIV infection [33], and chronic renal failure [34].
Conclusion
Although the IFN-g levels in the QFT-GIT decreased
after successful anti-TB treatment in most participants,
less than half of them had reversion to negativity of
QFT-GIT among young immunocompetent patients
with active TB. The reversion of the QFT-GIT with
anti-TB medication was more common among patients
Table 2 Difference and proportion of IFN-g levels at 6
months compared with those at baseline
Interferon-gamma level Number of participants (%/cumulative %)
Difference between baseline and 6 months (IU/ml)
≤ -8 7 (11.9/11.9)
> -8 and ≤ -5 9 (15.3/27.1)
> -5 and ≤ -2 11 (18.6/45.8)
> -2 and ≤ -1 14 (23.7/69.5)
> -1 and ≤ 0 15 (25.4/94.9)
> 0 and < 1.3 3 (5.1/100.0)
Proportion of participants with defined change (%)
≤ 10 15 (25.4/25.4)
> 10 and ≤ 25 14 (23.7/49.2)
> 25 and ≤ 50 13 (22.0/71.2)
> 50 and ≤ 100 14 (23.7/94.9)
> 100 and ≤ 360 3 (5.1/100.0)
Figure 3 Comparison of changes in the IFN-g level between patients with pulmonary tuberculosis according to the presence of
pleural effusion. Data were presented as mean ± standard error. * P<0.01 (between two groups)
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the diagnosis of active TB.
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